Advertisement

Human Albumin in the Management of Complications of Liver Cirrhosis

  • M. Bernardi
  • C. Maggioli
  • G. Zaccherini
Part of the Annual Update in Intensive Care and Emergency Medicine book series (AUICEM, volume 2012)

Abstract

Human serum albumin is the most abundant plasma protein, representing about 50% of the total protein content (3.5–5 g/l). Albumin is a protein of 585 amino acids and molecular weight 66 kDa encoded by a gene on chromosome 4 and is exclusively synthesized by liver cells, which release it directly into the blood stream without storage. Under physiological conditions, only 20–30% of hepatocytes are committed to the production of 9–12 g of albumin per day; therefore, the liver has a large functional reserve, so that it can increase the synthesis of this protein by 3–4 times, if necessary. The production of albumin is mainly regulated by the osmolarity and oncotic pressure of interstitial fluid in the liver extravascular space, but it is also induced by hormonal factors (insulin, cortisol and growth hormone) and inhibited by acute phase cytokines, such as interleukin (IL)-6 and tumor necrosis factor (TNF)-α [1].

Keywords

Human Serum Albumin Mean Arterial Pressure Human Albumin Spontaneous Bacterial Peritonitis Hepatorenal Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Quinlan GJ, Martin GS, Evans TW (2005) Albumin: biochemical properties and therapeutic potential. Hepatology 41: 1211–1219PubMedCrossRefGoogle Scholar
  2. 2.
    Mirici-Cappa F, Caraceni P, Domenicali M, et al (2011) How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. World J Gastroenterol 17: 3479–3486PubMedCrossRefGoogle Scholar
  3. 3.
    Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R, SAFE Study Investigators (2004) A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 350: 2247–2256Google Scholar
  4. 4.
    Delaney AP, Dan A, McCaffrey J, Finfer S (2011) The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis. Crit Care Med 39: 386–391PubMedCrossRefGoogle Scholar
  5. 5.
    Vincent JL (2009) Relevance of albumin in modern critical care medicine. Best Pract Res Clin Anaesthesiol 23: 183–191PubMedCrossRefGoogle Scholar
  6. 6.
    Evans TW (2002) Review article: albumin as a drug. Biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther 16: S6–S11CrossRefGoogle Scholar
  7. 7.
    Oettl K, Stauber RE (2007) Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br J Pharmacol 151: 580–590PubMedCrossRefGoogle Scholar
  8. 8.
    Sharma R, Gaze DC, Pellerin D, et al (2006) Ischemia-modified albumin predicts mortality in ESRD. Am J Kidney Dis 47: 493–502PubMedCrossRefGoogle Scholar
  9. 9.
    Van Belle E, Dallongeville J, Vicaut E, Degrandsart A, Baulac C, Montalescot G; OPERA Investigators (2010) Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study. Am Heart J 159: 570–576PubMedCrossRefGoogle Scholar
  10. 10.
    Henricksen JH, Siemssen O, Krintel JJ, Malchow-Møller A, Bendtsen F, Ring-Larsen (2001) Dynamics of albumin in plasma and acitic fluid in patients with cirrhosis. J Hepatol 34: 53–60CrossRefGoogle Scholar
  11. 11.
    Wood LJ, Colman J, Dudley FJ (1987) The relationship between portal pressure and plasma albumin in the development of cirrhotic ascites. J Gastroenterol Hepatol 2: 525–531CrossRefGoogle Scholar
  12. 12.
    Rector WG Jr, Ibarra F, Openshaw K, Hoefs JC (1986) Ascites kinetics in cirrhosis: relationship to plasma-ascites hydrostatic-oncotic balance and intensity of renal sodium retention. J Lab Clin Med 107: 412–419PubMedGoogle Scholar
  13. 13.
    Møller S, Henriksen JH (2008) Cardiovascular complications of cirrhosis. 57: 268–278Google Scholar
  14. 14.
    Ginés P, Titó L, Arroyo V, et al (1998) Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 94: 1493–1502Google Scholar
  15. 15.
    Sort P, Navasa M, Arroyo V, et al (1999) Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341: 403–409PubMedCrossRefGoogle Scholar
  16. 16.
    Martín-Llahí M, Pépin MN, Guevara M, et al (2008) Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 134: 1352–1359PubMedCrossRefGoogle Scholar
  17. 17.
    Sanyal AJ, Boyer T, Garcia-Tsao G, et al (2008) A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 134: 1360–1368PubMedCrossRefGoogle Scholar
  18. 18.
    Ginès A, Fernandez-Esparrach G, Monescillo A, et al (1996) Randomized controlled trial comparing albumin, dextran-70 and polygelin in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 111: 1002–1010PubMedCrossRefGoogle Scholar
  19. 19.
    European Association for the Study of the Liver (2010) EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis J Hepatol 53: 397–417CrossRefGoogle Scholar
  20. 20.
    Moreau R, Valla DC, Durand-Zaleski I, et al (2006) Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail. Liver Int 26: 46–54PubMedCrossRefGoogle Scholar
  21. 21.
    Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V (2007) Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 56: 1310–1318PubMedGoogle Scholar
  22. 22.
    Ginès P, Schrier RW (2009) Renal failure in cirrhosis. N Engl J Med 361: 1279–1290PubMedCrossRefGoogle Scholar
  23. 23.
    Ortega R, Gines P, Uriz J, et al (2002) Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of prospective, non-randomized study. Hepatology 36: 941–948PubMedGoogle Scholar
  24. 24.
    Gluud LL, Christensen K, Christensen E, Krag A (2010) Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 51: 576–584PubMedCrossRefGoogle Scholar
  25. 25.
    Angeli P, Volpin R, Gerunda G, et al (1999) Reversal of type 1 hepatorenal syndrome (HRS) with the combined administration of midodrine and octreotide. Hepatology 29: 1690–1697PubMedCrossRefGoogle Scholar
  26. 26.
    Alessandria C, Ottobrelli A, Debernardi-Venon W, et al (2007) Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 47: 499–505PubMedCrossRefGoogle Scholar
  27. 27.
    Caraceni P, Santi L, Mirici F, et al (2011) Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation. Dig Liver Dis 43: 242–245PubMedCrossRefGoogle Scholar
  28. 28.
    Sigal SH, Stanca CM, Fernandez J, Arroyo V, Navasa M (2007) Restricted use of albumin for spontaneous bacterial peritonitis. Gut 56: 597–599PubMedCrossRefGoogle Scholar
  29. 29.
    Fernández J, Monteagudo J, Bargallo X, et al (2005) A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 42: 627–634PubMedCrossRefGoogle Scholar
  30. 30.
    Clermont RJ, Vlahevic ZR, Chalmers TC, Adham NF, Curtis GW, Morrosin RS (1967) Intravenous therapy of massive ascites in patients with cirrhosis. Long-term effects on survival and frequency of renal failure. Gastroenterology 53: 220–228Google Scholar
  31. 31.
    Gentilini P, Casini-Raggi V, Di Fiore G, et al (1999) Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 30: 639–645PubMedCrossRefGoogle Scholar
  32. 32.
    Romanelli RG, La Villa G, Barletta G, et al (2006) Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol 12: 1403–1407PubMedGoogle Scholar
  33. 33.
    Watanabe A, Matsuzaki S, Moriwaki H, Suzuki K, Nishiguchi S (2004) Problems in serum albumin measurement and clinical significance of albumin microheterogeneity in cirrhotics. Nutrition 20: 351–357PubMedCrossRefGoogle Scholar
  34. 34.
    Oettl K, Stadlbauer V, Petter F, et al (2008) Oxidative damage of albumin in advanced liver disease. Biochim Biophys Acta 1782: 469–473Google Scholar
  35. 35.
    Jalan R, Schnurr K, Mookerjee RP, et al (2009) Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology 50: 555–564PubMedCrossRefGoogle Scholar
  36. 36.
    Oettl K, Stadlbauer V, Krisper P, Stauber RE (2009) Effect of extracorporeal liver support by molecular adsorbents recirculating system and Prometheus on redox state of albumin in acute-on-chronic liver failure. Ther Apher Dial 13: 431–436PubMedCrossRefGoogle Scholar
  37. 37.
    Karvellas CJ, Gibney N, Kutsogiannis D, Wendon J, Bain VG (2007) Bench-to-bedside review: current evidence for extracorporeal albumin dialysis systems in liver failure. Crit Care 11: 215PubMedCrossRefGoogle Scholar
  38. 38.
    Bañares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M, Relief Study Group (2010) Extracorporeal liver support with the molecular adsorbent recirculating system (MARS) in patients with acute-on-chronic liver failure (AOCLF). The RELIEF Trial. J Hepatol 52: S459–S460CrossRefGoogle Scholar
  39. 39.
    Rifai K, Kribben A, Gerken G, et al (2010) Extracorporeal liver support by fractionated plasma separation and adsorption (PROMETHEUS) in patients with acute-on-chronic liver failure (HELIOS Study): a prospective randomized controlled multicenter study. J Hepatol 52: S3 (abst)CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • M. Bernardi
  • C. Maggioli
  • G. Zaccherini

There are no affiliations available

Personalised recommendations